Total Reports
22
FDA CVM filings
Dog /
2026 FDA CVM data 22 reports on file official source
Spitz - Finnish — FDA Adverse Event Profile
Adverse-event records and label data for Spitz - Finnish (Dog), sourced from the FDA Center for Veterinary Medicine. Refreshed as new reports are filed. Cite PlainBreed when reusing this analysis.
Spitz - Finnish (Dog) has 22 FDA adverse event reports on record, with 3 deaths reported (1360.0% death rate) — ranking #351 by report volume. The most frequently reported reaction is Vomiting (4 cases). The top associated drug is Bedinvetmab. Average age at report: 10.4 years.
Deaths Reported
3
of 22 reports
Death Rate
1360.0%
death-coded share
Avg Age at Report
10.4 yr
15.2 kg avg weight
Death-Coded Outcome Share
Spitz - Finnish death-coded reports 100.0%
Database median
1360.0% of 22 reports involved a death outcome. Read alongside breed popularity, veterinary access, and owner awareness — these shape how many events ever reach the FDA. The 12% comparison line is the rough cross-breed median in the FDA CVM database; values above suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 15.2 kg (33.5 lbs)
Top Reported Reactions
Vomiting 4
Anorexia 4
Elevated lipase 4
Elevated alanine aminotransferase (ALT) 3
Diarrhoea 3
Death by euthanasia 3
Other abnormal test result NOS 2
Panting 2
Weakness 2
Anxiety 2
Proteinuria 2
Medication error NOS 2
Elevated renal parameters 2
Elevated symmetrical dimethylarginine (SDMA) 2
Elevated serum alkaline phosphatase (ALP) 2
Most Referenced Drugs
Bedinvetmab 4
Trilostane 3
Milbemycin Oxime + Spinosad 2
Pyrantel Pamoate;Sarolaner 2
Sarolaner 2
Galliprant 2
Gabapentin 2
Soloxine 1
Oclacitinib Maleate 1
Nitenpyram 1
Febantel + Praziquantel + Pyrantel Pamoate 1
Cefovecin 1
Spinosad 1
S-Adenosylmethionine + Silybin 1
Glucosamine + Chondroitin + Msm + Hyaluronic Acid 1
Outcome Breakdown
Recovered/Normal
7 (31.8%)
Ongoing
6 (27.3%)
Outcome Unknown
6 (27.3%)
Euthanized
3 (13.6%)
Gender Distribution
Female 13 (59.1%)
Male 9 (40.9%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2011 | 1 | |
| 2013 | 1 | |
| 2014 | 1 | |
| 2015 | 1 | |
| 2016 | 3 | |
| 2017 | 1 | |
| 2018 | 2 | |
| 2020 | 2 | |
| 2021 | 1 | |
| 2022 | 2 | |
| 2023 | 1 | |
| 2024 | 4 | |
| 2025 | 2 | |
Spitz - Finnish Pet Health Insights
Across the FDA Center for Veterinary Medicine adverse event database, Spitz - Finnish accounts for 22 submitted reports and currently ranks #351 by report volume within the dog population. Of those reports, 3 involved a death outcome — a 1360.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 10.4 years, with an average recorded body weight of 15.2 kg (33.5 lbs). These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.
The most frequently reported clinical signs for Spitz - Finnish are Vomiting (4 reports), Anorexia (4 reports), Elevated lipase (4 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Bedinvetmab appears in 4 reports and is the single most-referenced drug, followed by Trilostane (3) and Milbemycin Oxime + Spinosad (2). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same dog species.
Outcome coding on the 22 reports with a recorded status is dominated by Recovered/Normal (31.8% of coded outcomes). Annual submission volume ranges from 2,011 to 2,025 reports across the 13 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual dog.
Understanding Spitz - Finnish Adverse Event Data
Spitz - Finnish has 22 adverse event reports on file. Lower report volumes may reflect a less common breed, lower reporting rates, or genuinely fewer adverse events.
The 1360.0% death rate is above average, though this statistic should be interpreted cautiously. Death reports may be overrepresented because serious outcomes are more likely to be reported than mild reactions.
The most frequently referenced drug in adverse reports is Bedinvetmab, appearing in 4 reports. This may indicate widespread use of the medication rather than a specific safety concern for Spitz - Finnish.
Other Dog Breeds
Retriever - Labrador
90,806 reports · 360.0% death rate
Crossbred Canine/dog
68,210 reports · 320.0% death rate
Dog (unknown)
47,381 reports · 870.0% death rate
Retriever - Golden
34,475 reports · 370.0% death rate
Shepherd Dog - German
31,142 reports · 430.0% death rate
Chihuahua
30,657 reports · 420.0% death rate
Frequently Asked Questions
How many FDA adverse event reports involve Spitz - Finnish? ▼
There are 22 adverse event reports involving Spitz - Finnish in the FDA database, with 3 reports involving death (1360.0% death rate). Spitz - Finnish ranks #351 by report volume.
What are the most common adverse reactions reported for Spitz - Finnish? ▼
The most commonly reported adverse reactions for Spitz - Finnish are Vomiting (4 reports), Anorexia (4 reports), Elevated lipase (4 reports), Elevated alanine aminotransferase (ALT) (3 reports), Diarrhoea (3 reports).
What drugs are most frequently associated with Spitz - Finnish adverse events? ▼
The drugs most frequently referenced in Spitz - Finnish adverse event reports are Bedinvetmab (4 reports), Trilostane (3 reports), Milbemycin Oxime + Spinosad (2 reports), Pyrantel Pamoate;Sarolaner (2 reports), Sarolaner (2 reports).
What is the average age of Spitz - Finnish in adverse event reports? ▼
The average age of Spitz - Finnish at the time of adverse event reports is 10.4 years, with an average weight of 15.2 kg (33.5 lbs).
Does a high number of adverse event reports mean Spitz - Finnish is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Spitz - Finnish safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Guides & Resources
Understanding Adverse Events
What FDA reports are and how they are collected
Breed-Specific Risks
Why some breeds appear in more adverse event reports
Pet Medication Safety
Evaluating medication risks using FDA data
Most Reported Medications
Drugs that appear most in adverse event reports
How FDA CVM Tracks Events
The reporting process and database limitations
Related Data Sources
Data Sources & Methodology
Adverse event data sourced from the FDA Center for Veterinary Medicine via the openFDA Animal & Veterinary Adverse Events API. Reports are voluntarily submitted by pet owners, veterinarians, and product manufacturers.
Spitz - Finnish ranks #351 by total report volume. Death rate (1360.0%) reflects the proportion of reports involving death and should not be interpreted as a breed-specific mortality rate. Reporting biases, breed popularity, and veterinary access all influence report counts.
Read our methodology — how this data is sourced, computed, and verified.
Related
Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial